Evaluation of in vitro dissolution profiles of modified-release metoprolol succinate tablets crushed using mortar and pestle technique

Clinical practice guidelines advise against crushing modified-release dosage forms. Metoprolol succinate modified-release (MS-MR) tablets are commonly crushed in clinical practice to facilitate administration to patients with swallowing difficulties or using feeding tubes. To date, the effect of thi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmaceutical sciences 2024-03, Vol.194, p.106694-106694, Article 106694
Hauptverfasser: Kir, Fatma, Al-Sulaiti, Fatima K., Sahin, Selma
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 106694
container_issue
container_start_page 106694
container_title European journal of pharmaceutical sciences
container_volume 194
creator Kir, Fatma
Al-Sulaiti, Fatima K.
Sahin, Selma
description Clinical practice guidelines advise against crushing modified-release dosage forms. Metoprolol succinate modified-release (MS-MR) tablets are commonly crushed in clinical practice to facilitate administration to patients with swallowing difficulties or using feeding tubes. To date, the effect of this practice remains unexplored. The in vitro effects of crushing commercially available MS-MR tablets were explored using a holistic approach. Dissolution profiles of crushed versus whole MS-MR tablets were compared. Tablets were crushed to powder state using pragmatic method mimicking hospital practices. For standardization purposes, the same operator, duration (60 seconds), hand, and mortar-pestle apparatus were used. Dissolution studies were conducted per U.S. Pharmacopeia at pH 1.2, pH 4.5, and pH 6.8 with USP apparatus 2 (paddle) at rotation speed of 50 rpm at 37±0.5 °C in 500 mL dissolution media. Samples were withdrawn at predetermined time points. Percent drug dissolved was measured by validated UV–vis Spectrophotometry. Comprehensive analysis of the dissolution data was conducted using model-independent, model-dependent, and ANOVA-based approaches (SPSS v.23 at α=0.05). Similarity (f2) and difference (f1) factors were calculated to compare the dissolution profiles between crushed (CT) and whole tablets (WT). Goodness of fit (GOF) analysis examined the compliance between in vitro dissolution behaviors and several drug release models. Model selection was based on GOF plots, Akaike criteria and adjusted coefficient of determination (R2adj). Imaging and particle size distribution analysis were conducted to examine associated surface and morphologic changes. The dissolution profiles were not similar at pH 4.5 (f2=45.43, f1=18.97) and pH 6.8 (f2=31.47, f1=32.94). CT best fitted with Higuchi (pH 1.2: R2adj=0.9990), Weibull (pH 4.5: R2adj=0.9884), and Korsmeyer-Peppas (pH 6.8: R2adj=0.9719). Contrastingly, WT best fitted with Hopfenberg (pH 1.2: R2adj=0.9986), logistic (pH 4.5: R2adj=0.9839) and first-order (pH 6.8: R2adj=0.9979) models. A significant difference in the dissolution profiles was found between CT and WT using multivariate analysis of variance per time points and between the tablet forms (p=0.004). This was confirmed by unparalleled dissolution profiles. Crushing resulted in variations in particle size and surface morphological changes to the micropellets. Crushing practices change the dissolution profile of MS-MR tablets by deforming the surface mo
doi_str_mv 10.1016/j.ejps.2024.106694
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2912526254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0928098724000058</els_id><sourcerecordid>2912526254</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-a4f0a738009f1a123e323250a04791939445b721001904077ba9cfd94f5f68183</originalsourceid><addsrcrecordid>eNp9kMtuFDEQRS0EIkOSH2CBvGTTQ9ntflhig6IkIEViA2vL4y4Tj9ztweUeiR_gu-NhAktWlkrn3nIdxt4K2AoQ_Yf9FvcH2kqQqg76XqsXbCPGQTcwSHjJNqDl2IAehwv2hmgPAP04wGt20Y5C14TasN-3RxtXW0JaePI8LPwYSk58CkQprn_mh5x8iEgnYE5T8AGnJmNES8hnLKkCMUVOq3NhsQV5sbuIhbjLKz3ixFcKy4-azcVmbpeJH5BKrBy6xyX8XPGKvfI2El4_v5fs-93tt5vPzcPX-y83nx4a13aiNFZ5sEM7AmgvrJAttrKVHVhQgxa61Up1u0EKAKFBwTDsrHZ-0sp3vh_F2F6y9-fe-uW6loqZAzmM0S6YVjJSC9nJXnaqovKMupyIMnpzyGG2-ZcRYE7-zd6c_JuTf3P2X0PvnvvX3YzTv8hf4RX4eAawXnkMmA25gIvDKWR0xUwp_K__CTiwmH8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2912526254</pqid></control><display><type>article</type><title>Evaluation of in vitro dissolution profiles of modified-release metoprolol succinate tablets crushed using mortar and pestle technique</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Directory of Open Access Journals</source><source>EZB Electronic Journals Library</source><creator>Kir, Fatma ; Al-Sulaiti, Fatima K. ; Sahin, Selma</creator><creatorcontrib>Kir, Fatma ; Al-Sulaiti, Fatima K. ; Sahin, Selma</creatorcontrib><description>Clinical practice guidelines advise against crushing modified-release dosage forms. Metoprolol succinate modified-release (MS-MR) tablets are commonly crushed in clinical practice to facilitate administration to patients with swallowing difficulties or using feeding tubes. To date, the effect of this practice remains unexplored. The in vitro effects of crushing commercially available MS-MR tablets were explored using a holistic approach. Dissolution profiles of crushed versus whole MS-MR tablets were compared. Tablets were crushed to powder state using pragmatic method mimicking hospital practices. For standardization purposes, the same operator, duration (60 seconds), hand, and mortar-pestle apparatus were used. Dissolution studies were conducted per U.S. Pharmacopeia at pH 1.2, pH 4.5, and pH 6.8 with USP apparatus 2 (paddle) at rotation speed of 50 rpm at 37±0.5 °C in 500 mL dissolution media. Samples were withdrawn at predetermined time points. Percent drug dissolved was measured by validated UV–vis Spectrophotometry. Comprehensive analysis of the dissolution data was conducted using model-independent, model-dependent, and ANOVA-based approaches (SPSS v.23 at α=0.05). Similarity (f2) and difference (f1) factors were calculated to compare the dissolution profiles between crushed (CT) and whole tablets (WT). Goodness of fit (GOF) analysis examined the compliance between in vitro dissolution behaviors and several drug release models. Model selection was based on GOF plots, Akaike criteria and adjusted coefficient of determination (R2adj). Imaging and particle size distribution analysis were conducted to examine associated surface and morphologic changes. The dissolution profiles were not similar at pH 4.5 (f2=45.43, f1=18.97) and pH 6.8 (f2=31.47, f1=32.94). CT best fitted with Higuchi (pH 1.2: R2adj=0.9990), Weibull (pH 4.5: R2adj=0.9884), and Korsmeyer-Peppas (pH 6.8: R2adj=0.9719). Contrastingly, WT best fitted with Hopfenberg (pH 1.2: R2adj=0.9986), logistic (pH 4.5: R2adj=0.9839) and first-order (pH 6.8: R2adj=0.9979) models. A significant difference in the dissolution profiles was found between CT and WT using multivariate analysis of variance per time points and between the tablet forms (p=0.004). This was confirmed by unparalleled dissolution profiles. Crushing resulted in variations in particle size and surface morphological changes to the micropellets. Crushing practices change the dissolution profile of MS-MR tablets by deforming the surface morphology of embedded micropellets. Amounts of drug dissolved between CT and WT were not the same at the compared time points across gastrointestinal pH ranges. This suggests potential clinical impact on plasma-concentration profiles of critically ill patients using feeding tube. [Display omitted]</description><identifier>ISSN: 0928-0987</identifier><identifier>EISSN: 1879-0720</identifier><identifier>DOI: 10.1016/j.ejps.2024.106694</identifier><identifier>PMID: 38191064</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Clinical pharmacokinetics ; Crushing effect ; Delayed-Action Preparations ; Dissolution ; Drug Liberation ; Humans ; Metoprolol ; Pharmacokinetics ; Solubility ; Tablets</subject><ispartof>European journal of pharmaceutical sciences, 2024-03, Vol.194, p.106694-106694, Article 106694</ispartof><rights>2024 The Author(s)</rights><rights>Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c351t-a4f0a738009f1a123e323250a04791939445b721001904077ba9cfd94f5f68183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0928098724000058$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,860,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38191064$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kir, Fatma</creatorcontrib><creatorcontrib>Al-Sulaiti, Fatima K.</creatorcontrib><creatorcontrib>Sahin, Selma</creatorcontrib><title>Evaluation of in vitro dissolution profiles of modified-release metoprolol succinate tablets crushed using mortar and pestle technique</title><title>European journal of pharmaceutical sciences</title><addtitle>Eur J Pharm Sci</addtitle><description>Clinical practice guidelines advise against crushing modified-release dosage forms. Metoprolol succinate modified-release (MS-MR) tablets are commonly crushed in clinical practice to facilitate administration to patients with swallowing difficulties or using feeding tubes. To date, the effect of this practice remains unexplored. The in vitro effects of crushing commercially available MS-MR tablets were explored using a holistic approach. Dissolution profiles of crushed versus whole MS-MR tablets were compared. Tablets were crushed to powder state using pragmatic method mimicking hospital practices. For standardization purposes, the same operator, duration (60 seconds), hand, and mortar-pestle apparatus were used. Dissolution studies were conducted per U.S. Pharmacopeia at pH 1.2, pH 4.5, and pH 6.8 with USP apparatus 2 (paddle) at rotation speed of 50 rpm at 37±0.5 °C in 500 mL dissolution media. Samples were withdrawn at predetermined time points. Percent drug dissolved was measured by validated UV–vis Spectrophotometry. Comprehensive analysis of the dissolution data was conducted using model-independent, model-dependent, and ANOVA-based approaches (SPSS v.23 at α=0.05). Similarity (f2) and difference (f1) factors were calculated to compare the dissolution profiles between crushed (CT) and whole tablets (WT). Goodness of fit (GOF) analysis examined the compliance between in vitro dissolution behaviors and several drug release models. Model selection was based on GOF plots, Akaike criteria and adjusted coefficient of determination (R2adj). Imaging and particle size distribution analysis were conducted to examine associated surface and morphologic changes. The dissolution profiles were not similar at pH 4.5 (f2=45.43, f1=18.97) and pH 6.8 (f2=31.47, f1=32.94). CT best fitted with Higuchi (pH 1.2: R2adj=0.9990), Weibull (pH 4.5: R2adj=0.9884), and Korsmeyer-Peppas (pH 6.8: R2adj=0.9719). Contrastingly, WT best fitted with Hopfenberg (pH 1.2: R2adj=0.9986), logistic (pH 4.5: R2adj=0.9839) and first-order (pH 6.8: R2adj=0.9979) models. A significant difference in the dissolution profiles was found between CT and WT using multivariate analysis of variance per time points and between the tablet forms (p=0.004). This was confirmed by unparalleled dissolution profiles. Crushing resulted in variations in particle size and surface morphological changes to the micropellets. Crushing practices change the dissolution profile of MS-MR tablets by deforming the surface morphology of embedded micropellets. Amounts of drug dissolved between CT and WT were not the same at the compared time points across gastrointestinal pH ranges. This suggests potential clinical impact on plasma-concentration profiles of critically ill patients using feeding tube. [Display omitted]</description><subject>Clinical pharmacokinetics</subject><subject>Crushing effect</subject><subject>Delayed-Action Preparations</subject><subject>Dissolution</subject><subject>Drug Liberation</subject><subject>Humans</subject><subject>Metoprolol</subject><subject>Pharmacokinetics</subject><subject>Solubility</subject><subject>Tablets</subject><issn>0928-0987</issn><issn>1879-0720</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtuFDEQRS0EIkOSH2CBvGTTQ9ntflhig6IkIEViA2vL4y4Tj9ztweUeiR_gu-NhAktWlkrn3nIdxt4K2AoQ_Yf9FvcH2kqQqg76XqsXbCPGQTcwSHjJNqDl2IAehwv2hmgPAP04wGt20Y5C14TasN-3RxtXW0JaePI8LPwYSk58CkQprn_mh5x8iEgnYE5T8AGnJmNES8hnLKkCMUVOq3NhsQV5sbuIhbjLKz3ixFcKy4-azcVmbpeJH5BKrBy6xyX8XPGKvfI2El4_v5fs-93tt5vPzcPX-y83nx4a13aiNFZ5sEM7AmgvrJAttrKVHVhQgxa61Up1u0EKAKFBwTDsrHZ-0sp3vh_F2F6y9-fe-uW6loqZAzmM0S6YVjJSC9nJXnaqovKMupyIMnpzyGG2-ZcRYE7-zd6c_JuTf3P2X0PvnvvX3YzTv8hf4RX4eAawXnkMmA25gIvDKWR0xUwp_K__CTiwmH8</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Kir, Fatma</creator><creator>Al-Sulaiti, Fatima K.</creator><creator>Sahin, Selma</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240301</creationdate><title>Evaluation of in vitro dissolution profiles of modified-release metoprolol succinate tablets crushed using mortar and pestle technique</title><author>Kir, Fatma ; Al-Sulaiti, Fatima K. ; Sahin, Selma</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-a4f0a738009f1a123e323250a04791939445b721001904077ba9cfd94f5f68183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Clinical pharmacokinetics</topic><topic>Crushing effect</topic><topic>Delayed-Action Preparations</topic><topic>Dissolution</topic><topic>Drug Liberation</topic><topic>Humans</topic><topic>Metoprolol</topic><topic>Pharmacokinetics</topic><topic>Solubility</topic><topic>Tablets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kir, Fatma</creatorcontrib><creatorcontrib>Al-Sulaiti, Fatima K.</creatorcontrib><creatorcontrib>Sahin, Selma</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kir, Fatma</au><au>Al-Sulaiti, Fatima K.</au><au>Sahin, Selma</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of in vitro dissolution profiles of modified-release metoprolol succinate tablets crushed using mortar and pestle technique</atitle><jtitle>European journal of pharmaceutical sciences</jtitle><addtitle>Eur J Pharm Sci</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>194</volume><spage>106694</spage><epage>106694</epage><pages>106694-106694</pages><artnum>106694</artnum><issn>0928-0987</issn><eissn>1879-0720</eissn><abstract>Clinical practice guidelines advise against crushing modified-release dosage forms. Metoprolol succinate modified-release (MS-MR) tablets are commonly crushed in clinical practice to facilitate administration to patients with swallowing difficulties or using feeding tubes. To date, the effect of this practice remains unexplored. The in vitro effects of crushing commercially available MS-MR tablets were explored using a holistic approach. Dissolution profiles of crushed versus whole MS-MR tablets were compared. Tablets were crushed to powder state using pragmatic method mimicking hospital practices. For standardization purposes, the same operator, duration (60 seconds), hand, and mortar-pestle apparatus were used. Dissolution studies were conducted per U.S. Pharmacopeia at pH 1.2, pH 4.5, and pH 6.8 with USP apparatus 2 (paddle) at rotation speed of 50 rpm at 37±0.5 °C in 500 mL dissolution media. Samples were withdrawn at predetermined time points. Percent drug dissolved was measured by validated UV–vis Spectrophotometry. Comprehensive analysis of the dissolution data was conducted using model-independent, model-dependent, and ANOVA-based approaches (SPSS v.23 at α=0.05). Similarity (f2) and difference (f1) factors were calculated to compare the dissolution profiles between crushed (CT) and whole tablets (WT). Goodness of fit (GOF) analysis examined the compliance between in vitro dissolution behaviors and several drug release models. Model selection was based on GOF plots, Akaike criteria and adjusted coefficient of determination (R2adj). Imaging and particle size distribution analysis were conducted to examine associated surface and morphologic changes. The dissolution profiles were not similar at pH 4.5 (f2=45.43, f1=18.97) and pH 6.8 (f2=31.47, f1=32.94). CT best fitted with Higuchi (pH 1.2: R2adj=0.9990), Weibull (pH 4.5: R2adj=0.9884), and Korsmeyer-Peppas (pH 6.8: R2adj=0.9719). Contrastingly, WT best fitted with Hopfenberg (pH 1.2: R2adj=0.9986), logistic (pH 4.5: R2adj=0.9839) and first-order (pH 6.8: R2adj=0.9979) models. A significant difference in the dissolution profiles was found between CT and WT using multivariate analysis of variance per time points and between the tablet forms (p=0.004). This was confirmed by unparalleled dissolution profiles. Crushing resulted in variations in particle size and surface morphological changes to the micropellets. Crushing practices change the dissolution profile of MS-MR tablets by deforming the surface morphology of embedded micropellets. Amounts of drug dissolved between CT and WT were not the same at the compared time points across gastrointestinal pH ranges. This suggests potential clinical impact on plasma-concentration profiles of critically ill patients using feeding tube. [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38191064</pmid><doi>10.1016/j.ejps.2024.106694</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0928-0987
ispartof European journal of pharmaceutical sciences, 2024-03, Vol.194, p.106694-106694, Article 106694
issn 0928-0987
1879-0720
language eng
recordid cdi_proquest_miscellaneous_2912526254
source MEDLINE; Elsevier ScienceDirect Journals; Directory of Open Access Journals; EZB Electronic Journals Library
subjects Clinical pharmacokinetics
Crushing effect
Delayed-Action Preparations
Dissolution
Drug Liberation
Humans
Metoprolol
Pharmacokinetics
Solubility
Tablets
title Evaluation of in vitro dissolution profiles of modified-release metoprolol succinate tablets crushed using mortar and pestle technique
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T13%3A05%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20in%20vitro%20dissolution%20profiles%20of%20modified-release%20metoprolol%20succinate%20tablets%20crushed%20using%20mortar%20and%20pestle%20technique&rft.jtitle=European%20journal%20of%20pharmaceutical%20sciences&rft.au=Kir,%20Fatma&rft.date=2024-03-01&rft.volume=194&rft.spage=106694&rft.epage=106694&rft.pages=106694-106694&rft.artnum=106694&rft.issn=0928-0987&rft.eissn=1879-0720&rft_id=info:doi/10.1016/j.ejps.2024.106694&rft_dat=%3Cproquest_cross%3E2912526254%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2912526254&rft_id=info:pmid/38191064&rft_els_id=S0928098724000058&rfr_iscdi=true